Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Glomerulonephritis
How does your approach to the differential diagnosis of membranous nephropathy change when PLA2R positivity is detected alongside a chronic viral infection such as HIV, HBV, or HCV?
Related Questions
How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?
Do you prefer starting a SGLT2i before steroids in patients with IgA nephropathy and proteinuria > 1.0 gram/day who are unable to tolerate ACEi/ARB due to hypotension?
Under what circumstances would you consider treating with steroid therapy in a patient with HIV-associated nephropathy?
Do you routinely obtain serum anti-THSD7A and anti-NELL1 tests in your patients with nephrotic syndrome suspected secondary to membraneous nephropathy?
Do you use delayed-release budesonide over prednisone or methylprednisolone for the treatment of IgA nephropathy, considering the available safety and efficacy data?
How do you approach the management of patients with suspected membranous lupus nephritis who are found to have positive PLA2R antibodies?
What is your approach to treating IgA nephropathy in patients who also have IgA vasculitis?
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
Which clinical characteristics would prompt you to consider an oral factor B inhibitor such as iptacopan in the treatment of IgA nephropathy?
Do you assess for podocyte detachment in addition to effacement when considering the degree of glomerular injury and potential treatment options following a native kidney biopsy in a patient with proteinuria?
